Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 713 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan October 25, 2021 Mom Thinks Baby Died Until Firefighters Say The Family Dog Made... June 4, 2019 Load more HOT NEWS Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC... How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... Breaking down the new standards for cancer care proposed by NHS...
